Brahmer, J. R., Lee, J., Ciuleanu, T., Bernabe Caro, R., Nishio, M., Urban, L., Audigier-Valette, C., Lupinacci, L., Sangha, R., Pluzanski, A., Burgers, J., Mahave, M., Ahmed, S., Schoenfeld, A. J., Paz-Ares, L. G., Reck, M., Borghaei, H., O'Byrne, K. J., Gupta, R. G., Bushong, J., Li, L., Blum, S. I., Eccles, L. J., & Ramalingam, S. S. (2023). five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227. Journal of clinical oncology, 41(6), 1200–1212. http://access.bl.uk/ark:/81055/vdc_100179398088.0x00002b